Q3 2022 Results
Company overview
Financial performance
Cardiovascular
Ophthalmology
Financial review
2022 priorities
Innovation: Pipeline overview
Immunology
Neuroscience
Global Health
BeovuⓇ - VEGF Inhibitor
NCT04278417 (CRTH258D2301)
Indication
Diabetic retinopathy
Phase
Phase 3
Patients
706
Primary
Change from Baseline in BCVA
Outcome
Measures
Arms
Intervention
Target
Arm1: RTH258 (brolucizumab) 6 mg/50uL
Arm2: Panretinal photocoagulation laser initial treatment followed with
additional PRP treatment as needed
Patients with proliferative diabetic retinopathy
Patients
Read-out
Milestone(s)
2024
Publication
TBD
Appendix
Innovation: Clinical trials
References
Abbreviations
Oncology
Other
Biosimilars
84 Investor Relations | Q3 2022 Results
1 NOVARTIS | Reimagining MedicineView entire presentation